This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
Zimmer Biomet (ZBH) Is Up 0.07% in One Week: What You Should Know
by Zacks Equity Research
Does Zimmer Biomet (ZBH) have what it takes to be a top stock pick for momentum investors? Let's find out.
ZBH or MDT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ZBH vs. MDT: Which Stock Is the Better Value Option?
Zimmer Biomet (ZBH) Q4 Earnings Top Estimates, Margins Grow
by Zacks Equity Research
Zimmer Biomet (ZBH) benefits from strong sales growth across all geographies as well as segmental strengths at CER.
Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 1.77% and 0.92%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cardinal Health's (CAH) Q2 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) fiscal second-quarter earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.
Cerner (CERN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to have aided Cerner's (CERN) Q4 earnings. However, contraction in gross margin is likely to have been a dampener.
What's in the Cards for Zimmer Biomet (ZBH) in Q4 Earnings?
by Zacks Equity Research
Gains from developments in business segments are likely to get reflected in Zimmer Biomet's (ZBH) revenue results for the fourth quarter and 2019.
Zimmer Biomet (ZBH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher revenues, solid product portfolio and strong performance across six global business units are likely to have benefited Baxter's (BAX) Q4 earnings.
What's in Store for AmerisourceBergen (ABC) in Q1 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) Q1 earnings are likely to reflect the better-than-expected performance at Pharmaceutical Distribution and higher revenues.
Zimmer (ZBH) Stock Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent developments.
Zimmer Biomet Rides on Product Launches Despite Pricing Woes
by Zacks Equity Research
Zimmer Biomet's (ZBH) execution of its priority agenda including quality remediation, supply recovery efforts and product introductions looks impressive.
Stryker (SYK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine are likely to have contributed to Stryker's (SYK) Q4 earnings.
PerkinElmer (PKI) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Top-line growth and robust performance at Diagnostics segment are likely to have aided PerkinElmer's (PKI) Q4 earnings. However, forex is likely to have remained a woe.
What's in the Cards for Intuitive Surgical (ISRG) Q4 Earnings?
by Zacks Equity Research
Better-than-expected performance at Instruments & Accessories segment and da Vince procedure growth are likely to have benefited Intuitive Surgical's (ISRG) Q4 earnings.
Will Zimmer (ZBH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Zimmer (ZBH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Hold on to Zimmer (ZBH) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Zimmer (ZBH) on its stellar segmental performance in Q3.
Zimmer Biomet Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Zimmer Biomet (ZBH) is optimistic about maintaining growth momentum on several recent positive developments.
Zimmer Biomet Focuses on Priority Areas Despite Pricing Woes
by Zacks Equity Research
Zimmer Biomet (ZBH) is executing well within its priority areas like quality remediation, supply recovery efforts and product rollouts.
Zimmer (ZBH) Up 3.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zimmer (ZBH) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent positive developments.
Zimmer (ZBH) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Zimmer (ZBH) is likely to maintain the current high on a number of favorable factors.
Zimmer Biomet (ZBH) Q3 Earnings Top, Operating Margin Falls
by Zacks Equity Research
Zimmer Biomet (ZBH) gains from strong sales growth across all geographies and most operating segments in Q3.
Zimmer Biomet (ZBH) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 0.57% and 1.02%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Roster for Nov 5: BDX, ZBH & More
by Urmimala Biswas
Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.